Plain-English translation of NCT07753603 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help people with moderate to severe thyroid eye disease (a condition where the eyes become inflamed and uncomfortable due to thyroid problems). Researchers want to understand whether this medication works better than a placebo (a dummy pill with no active ingredient) and whether it's safe to use. The study will involve about 130 people over 24 weeks.
Thyroid eye disease can cause significant discomfort, vision problems, and quality-of-life challenges that current treatments don't always fully address. This trial is testing whether this new medication could offer patients a better treatment option.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be randomly assigned to either receive the new medication or a placebo pill, taken twice daily for 24 weeks. You won't know which one you're taking (this is called 'blinded'). You'll have regular clinic visits to check how you're doing, have your eyes examined, and report any side effects. After the initial 24-week period, some participants may be offered continued treatment with the actual medication to see how long the benefits last.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Sling Therapeutics, Inc.
Enrollment target
~130 participants
Started
August 2026
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cathy Radovich
Sling Therapeutics, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.